The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
An interim analysis of a phase II study using an epigenetic biomarker (CHFR methylation status) to personalize chemotherapy in patients with operable esophageal cancer.
Ronan Joseph Kelly
No relevant relationships to disclose
John Wrangle
No relevant relationships to disclose
Russell K. Hales
No relevant relationships to disclose
Daniela Molena
No relevant relationships to disclose
Stephen C. Yang
No relevant relationships to disclose
Kristen Rodgers
No relevant relationships to disclose
Margaret Lang
No relevant relationships to disclose
Jeffrey Reynolds
No relevant relationships to disclose
Tammy Beckman
No relevant relationships to disclose
Amanda Choflet
No relevant relationships to disclose
Malcolm Brock
Other Remuneration - MDxHealth
James Gordon Herman
Research Funding - MDxHealth
Other Remuneration - MDxHealth